A skin cancer drug aimed at stopping the disease from using the so-called hedgehog pathway was approved by the Food and Drug Administration more than a month ahead of schedule.
Vismodegib, a once-a-day capsule that will be marketed by South San Francisco-based Genentech Inc. as Erivedge, was approved for use by patients with basal cell carcinoma that has spread to other parts of the body, has returned after surgery or cannot be treated with surgery or radiation.
The drug was worked on by Genentech and Lexington, Mass.-based Curis Inc. (NASDAQ: CRIS), but its Bay Area roots run deep. Labs at the University of California, San Francisco, Children’s Hospital Oakland Research Institute and Stanford University worked on the drug.
No comments:
Post a Comment